Revenue of $123 million, revenue growth of 28%Year to Date Organic Revenue growth of 24% (1)Loss of $10.1 million due to high stock-based compensation expenses. Adjusted Net Income of $6 millionAdjusted EBITDA of $14.1 million (1) Reaffirms full year 2026 revenue and Adjusted EBITDA guidance HERZLIYA, Israel, Aug. 10, 2026 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX, TASE: NYAX), a global commerce payments and loyalty platform designed to help merchants scale their business, today announced its financial results for the second quarter ended June 30, 2026. “We had a strong second quarter, with continued execution across the business. Revenue grew 28% to $123 million, with organic revenue growth of 24% year to date, our installed base surpassed 1.55 million devices, and our customer base reached 125,000. Our growth algorithm continues...

CHICAGO, Aug. 10, 2026 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, today reported its results for the second quarter 2026. GCM Grosvenor issued a detailed presentation of its results to the Public Shareholders section of GCM Grosvenor’s website at https://www.gcmgrosvenor.com/shareholder-events. The firm’s Board of Directors also approved a $0.12 per share dividend payable on September 15, 2026 to shareholders on record September 1, 2026. Conference CallA conference call to discuss GCM Grosvenor’s financial results will be held today, Monday, August 10, 2026, at 10:00 a.m. ET. The call will be accessible via public webcast from the Public Shareholders section of GCM Grosvenor’s website at https://www.gcmgrosvenor.com/shareholder-events, and a replay of the live broadcast...

RESTON, Va., Aug. 10, 2026 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering and infrastructure asset management firm, today announced financial results for the second quarter ended June 30, 2026. “We made meaningful advances during the second quarter, with net service billing increasing by more than 19%, organic growth accelerating to 13%, Adjusted EBITDA margin nearing 19%, and backlog reaching $659 million,” said Gary Bowman, founder and CEO. “The results reflect the strength of our underlying business and our long-range strategy. The quarter was a pivotal period of project mobilizations and strategic investments for several key initiatives expected to contribute meaningfully in the second half and beyond. “During the quarter, we upgraded assets and resources that support our geospatial collection...

Reaffirms Full Year 2026 Guidance BRENTWOOD, Tenn., Aug. 10, 2026 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights (All comparisons are year-over-year unless otherwise noted)Revenue increased 2.7% for the second quarterSame-facility revenues increased 5.0% for the second quarter Same-facility cases increased 0.3% for the second quarterNet loss attributable to Surgery Partners, Inc. was $15.0 million for the second quarterAdjusted EBITDA was $125.2 million for the second quarter2026 GuidanceFull year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA...

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer’s Association International Conference (AAIC) 2026 reinforce neflamapimod’s treatment effect in pure DLB and support 50 mg TID dose for planned Phase 3 trial Initial, 12-week biomarker data from Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA) to be presented at the 15th International Conference on Frontotemporal Dementia (ISFTD) in October 2026; full 12-week and initial, 24-week biomarker data to be presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in November...

Second quarter gross margin expanded 80 basis points to 22.3% despite 3.5% lower sales from last year First six months gross margin expanded 60 basis points to 21.8% on 7.6% higher sales over last year Second quarter net income increased $0.2 million over last year to $3.1 million; Adjusted EBITDA1 of $11.7 million declined $0.6 million, or 4.7%, from last year First six months net income increased $3.8 million over last year to $4.6 million; Adjusted EBITDA1 of $16.8 million increased $2.8 million, or 19.6%, over last year Generated quarterly operating cash flow of $17.9 million, improving Gross Leverage Ratio1 to 1.0x Backlog1 increased 17.4% during the quarter supporting the Company’s reaffirmed 2026 guidancePITTSBURGH, Aug. 10, 2026 (GLOBE NEWSWIRE) — L.B. Foster Company (Nasdaq: FSTR), a global technology solutions...

Record-Setting Second Quarter Highlighted by Strong Orders, Up 191 Percent and Backlog Above $1.8 BillionThermon Integration Delivering Synergies Ahead of PlanCompany Raises Full Year Consolidated 2026 Outlook ADDISON, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) (“CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its financial results for the second quarter of 2026. Highlights for the Quarter (1) First quarter as a combined company following the June 1, 2026 acquisition of ThermonOrders of $798.5 million, up 191 percent; backlog of $1,819.1 million, up 164 percent Revenue of $285.0 million, up 54 percent Gross profit of $86.5 million, up 29 percent; gross margin of...

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of 2027Cash, cash equivalents, and investments of $461 million as of June 30, 2026 expected to provide runway into the fourth quarter of 2028SAN...

Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 (66.5%), MDA (41.2%) and PASI90 (61%), supporting the broad multidomain efficacy profile of sonelokimab in psoriatic arthritis Meaningful and statistically significant improvements were seen across patient-reported outcomes and physical function measures, including HAQ-DI and SF-36 PCS Blinded safety analysis suggests a profile consistent with previous studies and no new safety signals were identified, reinforcing sonelokimab’s potential to become a leading treatment option for patients living with psoriatic arthritis, and enabling MoonLake’s...

AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year SAN FRANCISCO and BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today reported second quarter 2026 financial results, recent corporate updates and pipeline progress. “The second quarter marked a transformational period for Apogee,”...